Early start to certolizumab good for Crohn's patients

04/3/2010 | Medscape (free registration)

Starting Crohn's disease patients on certolizumab pegol shortly after diagnosis leads to particularly good results, according to a study in the American Journal of Gastroenterology. The researchers said additional study is needed but that the benefit-risk ratio "may well be acceptable" for using tumor necrosis factor-alpha blocking agents in early disease.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC